Acta Medica Iranica. 2012; 50 (8): 541-546
em Inglês
| IMEMR
| ID: emr-149988
ABSTRACT
Stem cell-based therapies have recently opened up new horizons for treatment of various types of diseases including diabetes mellitus. However, long-term efficacy and safety of these novel modalities still remain a serious question. Hereby, we aim to report the one-year follow-up results in the diabetic patients who underwent fetal liver-derived hematopoietic stem cell allotransplantation. Fifty six patients with type one [n=30] and type two [n=26] diabetes, aged 10-58 years old [32.8 +/- 16.3] were divided into the intervention and placebo group. The patients in the intervention group underwent fetal liver-derived hematopoietic stem cell transplantation while the patients in the placebo group received 5 ml of normal saline both via an intravenous route. The patients were visited at regular intervals to evaluate the efficacy of transplantation in glycemic control as well as possible complications. In the 6[th] month of the follow-up, there was a significant decrease in HbA[1]c levels in all groups without any rise in the fasting c-peptide. However, none of the precipitants transiently or continuously became insulin free in the first year after transplantation. It can be concluded that, in this study, fetal liver-derived hematopoietic stem cell transplantation had no significant effects on glycemic control. The heterogeneity of our patients might account for the negative results. Hence, longer follow-up results will be reported in the near future.
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Idioma:
Inglês
Revista:
Acta Med. Iran.
Ano de publicação:
2012
Similares
MEDLINE
...
LILACS
LIS